News & Updates

Show Multimedia Only

Olorofim shows promise in invasive fungal disease

23 Jul 2025

In patients with invasive fungal disease (IFD) who have few or no treatment options, olorofim demonstrates efficacy and good tolerability, according to the results of a single-arm, open-label phase IIb study.

Olorofim shows promise in invasive fungal disease

23 Jul 2025

COVID-19 booster shots confer protection against severe disease in cancer patients

23 Jul 2025 by

Patients with cancer who have received COVID-19 booster vaccinations are better protected against severe disease, according to real-world data from four healthcare systems in the US.

COVID-19 booster shots confer protection against severe disease in cancer patients

23 Jul 2025

Apremilast trims fat mass, reducing CV events in PsA

23 Jul 2025

Treatment with apremilast results in fat mass reduction among patients with psoriatic arthritis (PsA), indicating positive cardiovascular (CV) and metabolic effects, which may lower the risk of CV events, a recent study has shown.

Apremilast trims fat mass, reducing CV events in PsA

23 Jul 2025

Delays, higher costs in tocilizumab therapy add to burden of GCA

23 Jul 2025

Significant delays occur in the initiation of tocilizumab (TCZ) therapy among patients with giant cell arteritis (GCA), reports a US study.

Delays, higher costs in tocilizumab therapy add to burden of GCA

23 Jul 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-June-2025

23 Jul 2025

New drug applications approved by US FDA as of 1-15 June 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-June-2025

23 Jul 2025

Nirsevimab efficacy against RSV-LRTI hospitalization sustained at 6 months

23 Jul 2025 by

Updated results from the phase IIIB HARMONIE trial demonstrate sustained efficacy of the long-acting monoclonal antibody nirsevimab against respiratory syncytial virus-associated lower respiratory tract infection (RSV-LRTI) hospitalization through day 181 post-dose.

Nirsevimab efficacy against RSV-LRTI hospitalization sustained at 6 months

23 Jul 2025

Add-on semaglutide improves glycaemic control, weight loss in adults with T1D, obesity

23 Jul 2025 by

The addition of once-weekly semaglutide to an automated insulin delivery (AID) system leads to significantly improved time in range (TIR) and reduced body weight in adults with type 1 diabetes (T1D) and obesity compared with AID alone, according to the ADJUST-T1D* trial presented at ADA 2025.

Add-on semaglutide improves glycaemic control, weight loss in adults with T1D, obesity

23 Jul 2025

Original New Drug Application Approvals by US FDA (16-30 June 2025)

23 Jul 2025

New drug applications approved by US FDA as of 16-30 June 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.